Ser48
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser48  -  p73 (human)

Site Information
VVGGTDssMDVFHLE   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 52434701

In vivo Characterization
Methods used to characterize site in vivo:
flow cytometry ( 1 ) , immunoprecipitation ( 1 ) , mass spectrometry ( 1 ) , microscopy-colocalization with upstream kinase ( 1 ) , mutation of modification site ( 2 ) , western blotting ( 1 )
Disease tissue studied:
bone cancer ( 1 , 2 ) , osteosarcoma ( 2 ) , cancer, squamous cell carcinoma ( 2 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
PLK2 (human) ( 1 , 2 )
Kinases, in vitro:
PLK2 (human) ( 1 , 2 )
Treatments:
adriamycin ( 1 ) , cisplatin ( 1 ) , ELN582646 ( 2 ) , siRNA ( 2 )

Downstream Regulation
Effects of modification on p73:
activity, inhibited ( 2 ) , intracellular localization ( 1 )
Effects of modification on biological processes:
apoptosis, induced ( 2 ) , apoptosis, inhibited ( 1 ) , cell cycle regulation ( 1 ) , cell growth, induced ( 1 ) , cell motility, induced ( 1 ) , transcription, inhibited ( 1 )

References 

1

Hu ZB, et al. (2016) PLK2 phosphorylates and inhibits enriched TAp73 in human osteosarcoma cells. Cancer Med 5, 74-87
26625870   Curated Info

2

Hu Z, et al. (2015) Polo-like kinase 2 acting as a promoter in human tumor cells with an abundance of TAp73. Onco Targets Ther 8, 3475-88
26640387   Curated Info